Human-derived bacteria that induce proliferation or accumulation of regulatory T cells

Patent metadata

Field	Value
Publication number	US-10624933-B2
Application number	US-201916427899-A
Country	US
Kind code	B2
Filing date	May 31, 2019
Priority date	Dec 1, 2011
Publication date	Apr 21, 2020
Grant date	Apr 21, 2020

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

First claim

What is claimed is:

1. A method of treating an autoimmune disease in a subject, the method comprising administering a pharmaceutical composition comprising a purified bacterial mixture consisting of bacteria comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:39; SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42 to the subject in an amount sufficient to treat the autoimmune disease.

2. The method of claim 1 , wherein the autoimmune disease is organ transplant rejection, inflammatory bowel disease (IBD), ulcerative colitis, pouchitis, Crohn's disease, sprue, rheumatoid arthritis, Type 1 diabetes, graft versus host disease, or multiple sclerosis.

3. The method of claim 2 , wherein the autoimmune disease is inflammatory bowel disease (IBD), ulcerative colitis, pouchitis, or Crohn's disease.

4. The method of claim 1 , wherein the bacteria are human-derived bacteria.

5. The method of claim 1 , wherein the bacteria are isolated from a chloroform-treated fecal sample.

6. The method of claim 1 , wherein the bacteria are isolated from a heat-treated fecal sample.

7. The method of claim 1 , wherein at least a portion of the bacteria are in spore-form.

8. The method of claim 1 , further comprising a pharmaceutically acceptable excipient.

9. The method of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

10. The method of claim 1 , wherein the pharmaceutical composition comprises one or more enteric polymers.

Assignees

• Univ Tokyo
• School Corporation Azabu Veterinary Medicine Educational Inst

Inventors

• Honda Kenya
• Atarashi Koji
• Tanoue Takeshi
• Hattori Masahira
• Morita Hidetoshi

Classifications

• A61K35/74 Primary

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C12Q1/04

  Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)} · CPC title

• A61K35/747

  Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title